Teva Pharmaceutical Industries Limited

(NASDAQ:TEVA)

View:
Quarterly Data
Annual Data
Note: All numbers in thousands

	Jun 30, 2008	Mar 31, 2008	Dec 31, 2007	Sep 30, 2007
Operating revenue
Total Revenue	2,823,000	2,572,000	2,576,000	2,366,000
Operating Revenue	2,823,000	2,572,000	2,576,000	2,366,000
Adjustments To Revenue	—	—	—	—
Cost Of Sales	1,196,000	1,074,000	1,089,000	1,002,000
Cost Of Sales With Depreciation	1,318,000	1,200,000	1,229,000	1,116,000
Gross Operating Profit	1,627,000	1,498,000	1,487,000	1,364,000
Operating Expenses
Research And Development Expenses	198,000	179,000	168,000	141,000
Selling General And Administrative Expenses	669,000	514,000	518,000	458,000
Advertising Expenses	—	—	—	—
Operating Income Before Depreciation	760,000	805,000	801,000	765,000
Operating Income	638,000	297,000	661,000	651,000
Depreciation	122,000	126,000	140,000	114,000
Depreciation Unreconciled	—	—	—	—
Amortization	—	—	—	—
Amortization Of Intangibles	—	—	—	—
Operating Income After Depreciation	638,000	679,000	661,000	651,000
Non Operating Expenses
Interest Expense	28,000	57,000	161,000	3,000
Pre Tax Income	611,000	241,000	653,000	650,000
Income Taxes	68,000	93,000	84,000	125,000
Minority Interest	2,000	1,000	-1,000	—
Income Before Income Taxes	610,000	240,000	658,000	648,000
Net Income From Continuing Operations	539,000	147,000	570,000	525,000
Net Income From Discontinued Operations	—	—	—	—
Net Income From Total Operations	539,000	147,000	570,000	525,000
Non Recurring Events
Extraordinary Income Losses	—	—	—	—
Income From Cummulated Effect Of Accounting Changes	—	—	—	—
Income From Tax Loss Carryforward	—	—	—	—
Other Gains And Losses	—	—	—	—
Total Net Income	539,000	147,000	570,000	525,000
Normalized Income	539,000	529,000	570,000	525,000
NetIncome Available For Common	539,000	147,000	570,000	525,000
Preferred Dividends	—	—	—	—
Excise Taxes	—	—	—	—

	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005	Dec 31, 2004
Operating revenue
Total Revenue	9,408,000	8,408,000	5,250,400	4,798,900
Operating Revenue	9,408,000	8,408,000	5,250,400	4,798,900
Adjustments To Revenue	—	—	—	—
Cost Of Sales	4,010,000	3,718,000	2,527,300	2,339,200
Cost Of Sales With Depreciation	4,531,000	4,149,000	2,769,800	2,559,600
Gross Operating Profit	5,398,000	4,690,000	2,723,100	2,459,700
Operating Expenses
Research And Development Expenses	581,000	495,000	368,900	338,400
Selling General And Administrative Expenses	1,901,000	1,572,000	798,800	696,500
Advertising Expenses	—	—	—	—
Operating Income Before Depreciation	2,916,000	2,623,000	1,555,400	1,424,800
Operating Income	2,395,000	801,000	1,312,900	577,800
Depreciation	521,000	431,000	242,500	220,400
Depreciation Unreconciled	—	—	—	—
Amortization	—	—	—	—
Amortization Of Intangibles	—	—	—	—
Operating Income After Depreciation	2,395,000	2,192,000	1,312,900	1,204,400
Non Operating Expenses
Interest Expense	200,000	179,000	4,300	—
Pre Tax Income	2,350,000	703,000	1,310,300	602,500
Income Taxes	397,000	155,000	236,200	267,200
Minority Interest	1,000	2,000	1,800	3,500
Income Before Income Taxes	2,353,000	706,000	1,308,600	603,700
Net Income From Continuing Operations	1,952,000	546,000	1,072,300	331,800
Net Income From Discontinued Operations	—	—	—	—
Net Income From Total Operations	1,952,000	546,000	1,072,300	331,800
Non Recurring Events
Extraordinary Income Losses	—	—	—	—
Income From Cummulated Effect Of Accounting Changes	—	—	—	—
Income From Tax Loss Carryforward	—	—	—	—
Other Gains And Losses	—	—	—	—
Total Net Income	1,952,000	546,000	1,072,300	331,800
Normalized Income	1,952,000	1,937,000	1,072,300	958,400
NetIncome Available For Common	1,952,000	546,000	1,072,300	331,800
Preferred Dividends	—	—	—	—
Excise Taxes	—	—	—	—